CA1297406C - Methode pour la detection et la quantification des ligands dans des liquides - Google Patents

Methode pour la detection et la quantification des ligands dans des liquides

Info

Publication number: CA1297406C
Authority: CA; Canada
Prior art keywords: biotin; ligand; interest; avidin; labeled
Prior art date: 1987-01-15
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA000556618A

Other languages

English (en)

Inventor

Richard C. Hevey

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Individual

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-01-15

Filing date

1988-01-15

Publication date

1992-03-17

1987-02-11 Priority claimed from US07/013,581 external-priority patent/US4863876A/en

1988-01-15 Application filed by Individual filed Critical Individual

1992-03-17 Application granted granted Critical

1992-03-17 Publication of CA1297406C publication Critical patent/CA1297406C/fr

2009-03-17 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

239000003446 ligand Substances 0.000 title claims abstract description 168
238000000034 method Methods 0.000 title claims abstract description 100
239000007788 liquid Substances 0.000 title claims abstract description 79
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims abstract description 350
229960002685 biotin Drugs 0.000 claims abstract description 187
239000011616 biotin Substances 0.000 claims abstract description 187
235000020958 biotin Nutrition 0.000 claims abstract description 175
108090001008 Avidin Proteins 0.000 claims abstract description 159
238000002875 fluorescence polarization Methods 0.000 claims abstract description 85
230000009870 specific binding Effects 0.000 claims abstract description 85
239000000427 antigen Substances 0.000 claims description 85
102000036639 antigens Human genes 0.000 claims description 66
108091007433 antigens Proteins 0.000 claims description 66
238000009739 binding Methods 0.000 claims description 64
230000027455 binding Effects 0.000 claims description 51
238000011534 incubation Methods 0.000 claims description 19
238000005259 measurement Methods 0.000 claims description 15
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 claims description 6
229940000425 combination drug Drugs 0.000 claims description 2
238000003018 immunoassay Methods 0.000 abstract description 20
239000000126 substance Substances 0.000 abstract description 16
238000003556 assay Methods 0.000 description 57
230000010287 polarization Effects 0.000 description 51
239000012071 phase Substances 0.000 description 42
239000000306 component Substances 0.000 description 27
229960002143 fluorescein Drugs 0.000 description 23
239000000523 sample Substances 0.000 description 22
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
238000006243 chemical reaction Methods 0.000 description 16
239000003153 chemical reaction reagent Substances 0.000 description 16
230000035945 sensitivity Effects 0.000 description 13
238000007792 addition Methods 0.000 description 12
239000000243 solution Substances 0.000 description 12
239000002953 phosphate buffered saline Substances 0.000 description 11
230000005284 excitation Effects 0.000 description 10
241000283973 Oryctolagus cuniculus Species 0.000 description 8
239000000872 buffer Substances 0.000 description 8
230000000694 effects Effects 0.000 description 8
239000000463 material Substances 0.000 description 8
239000000203 mixture Substances 0.000 description 8
150000003384 small molecules Chemical class 0.000 description 8
239000007790 solid phase Substances 0.000 description 7
CKRJGDYKYQUNIM-UHFFFAOYSA-N 3-fluoro-2,2-dimethylpropanoic acid Chemical compound FCC(C)(C)C(O)=O CKRJGDYKYQUNIM-UHFFFAOYSA-N 0.000 description 6
108020004414 DNA Proteins 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
YMXHPSHLTSZXKH-RVBZMBCESA-N (2,5-dioxopyrrolidin-1-yl) 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)ON1C(=O)CCC1=O YMXHPSHLTSZXKH-RVBZMBCESA-N 0.000 description 5
241000283707 Capra Species 0.000 description 5
238000013459 approach Methods 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
230000007423 decrease Effects 0.000 description 5
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Substances N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 5
230000005855 radiation Effects 0.000 description 5
239000011324 bead Substances 0.000 description 4
230000009137 competitive binding Effects 0.000 description 4
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 4
229920002521 macromolecule Polymers 0.000 description 4
230000028161 membrane depolarization Effects 0.000 description 4
239000002244 precipitate Substances 0.000 description 4
-1 DN~ Proteins 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
239000000020 Nitrocellulose Substances 0.000 description 3
239000012491 analyte Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
238000001514 detection method Methods 0.000 description 3
239000007850 fluorescent dye Substances 0.000 description 3
229940125396 insulin Drugs 0.000 description 3
150000002605 large molecules Chemical class 0.000 description 3
229920001220 nitrocellulos Polymers 0.000 description 3
230000036963 noncompetitive effect Effects 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
238000000926 separation method Methods 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000002904 solvent Substances 0.000 description 3
150000003431 steroids Chemical class 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
YMXHPSHLTSZXKH-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 5-(2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl)pentanoate Chemical compound S1CC2NC(=O)NC2C1CCCCC(=O)ON1C(=O)CCC1=O YMXHPSHLTSZXKH-UHFFFAOYSA-N 0.000 description 2
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
VWLAGVVQCMHHJW-UHFFFAOYSA-N 1-(2-aminoethyl)-3-(3',6'-dihydroxy-3-oxospiro[2-benzofuran-1,9'-xanthene]-5-yl)thiourea Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C21OC(=O)C1=CC(NC(=S)NCCN)=CC=C21 VWLAGVVQCMHHJW-UHFFFAOYSA-N 0.000 description 2
XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 2
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
102000004877 Insulin Human genes 0.000 description 2
108090001061 Insulin Proteins 0.000 description 2
108091028043 Nucleic acid sequence Proteins 0.000 description 2
239000004677 Nylon Substances 0.000 description 2
239000004793 Polystyrene Substances 0.000 description 2
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
241000251539 Vertebrata <Metazoa> Species 0.000 description 2
230000001745 anti-biotin effect Effects 0.000 description 2
208000016610 ataxia-hypogonadism-choroidal dystrophy syndrome Diseases 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
230000002860 competitive effect Effects 0.000 description 2
238000010668 complexation reaction Methods 0.000 description 2
229960001760 dimethyl sulfoxide Drugs 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
238000001506 fluorescence spectroscopy Methods 0.000 description 2
OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
239000011521 glass Substances 0.000 description 2
230000005283 ground state Effects 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
239000007791 liquid phase Substances 0.000 description 2
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
229920001778 nylon Polymers 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
229920002223 polystyrene Polymers 0.000 description 2
239000011148 porous material Substances 0.000 description 2
150000004032 porphyrins Chemical class 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
238000012545 processing Methods 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
201000005404 rubella Diseases 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
229940034208 thyroxine Drugs 0.000 description 2
XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 2
229910052724 xenon Inorganic materials 0.000 description 2
FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 description 2
DNXHEGUUPJUMQT-UHFFFAOYSA-N (+)-estrone Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 DNXHEGUUPJUMQT-UHFFFAOYSA-N 0.000 description 1
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
UCTWMZQNUQWSLP-UHFFFAOYSA-N Adrenaline Natural products CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 1
206010001497 Agitation Diseases 0.000 description 1
102000015427 Angiotensins Human genes 0.000 description 1
108010064733 Angiotensins Proteins 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
DNXHEGUUPJUMQT-CBZIJGRNSA-N Estrone Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 DNXHEGUUPJUMQT-CBZIJGRNSA-N 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
YWYQTGBBEZQBGO-BERLURQNSA-N Pregnanediol Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](O)C)[C@@]2(C)CC1 YWYQTGBBEZQBGO-BERLURQNSA-N 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
YWYQTGBBEZQBGO-UHFFFAOYSA-N UC1011 Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(O)C)C1(C)CC2 YWYQTGBBEZQBGO-UHFFFAOYSA-N 0.000 description 1
241000700605 Viruses Species 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
208000009956 adenocarcinoma Diseases 0.000 description 1
229940102884 adrenalin Drugs 0.000 description 1
102000013529 alpha-Fetoproteins Human genes 0.000 description 1
108010026331 alpha-Fetoproteins Proteins 0.000 description 1
210000004381 amniotic fluid Anatomy 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000003172 anti-dna Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
102000023732 binding proteins Human genes 0.000 description 1
239000013060 biological fluid Substances 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
230000006287 biotinylation Effects 0.000 description 1
238000007413 biotinylation Methods 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
230000001609 comparable effect Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
229940052810 complex b Drugs 0.000 description 1
230000000536 complexating effect Effects 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000009792 diffusion process Methods 0.000 description 1
229960005156 digoxin Drugs 0.000 description 1
LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000003480 eluent Substances 0.000 description 1
229960005309 estradiol Drugs 0.000 description 1
229930182833 estradiol Natural products 0.000 description 1
229960003399 estrone Drugs 0.000 description 1
230000005281 excited state Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
229960000304 folic acid Drugs 0.000 description 1
235000019152 folic acid Nutrition 0.000 description 1
239000011724 folic acid Substances 0.000 description 1
230000002949 hemolytic effect Effects 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
229940072221 immunoglobulins Drugs 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000002156 mixing Methods 0.000 description 1
229960005181 morphine Drugs 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
239000000186 progesterone Substances 0.000 description 1
229960003387 progesterone Drugs 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
239000012521 purified sample Substances 0.000 description 1
238000011002 quantification Methods 0.000 description 1
238000012207 quantitative assay Methods 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 1
241000894007 species Species 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229960003604 testosterone Drugs 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
239000011782 vitamin Substances 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Biotechnology (AREA)
Analytical Chemistry (AREA)
Cell Biology (AREA)
Pathology (AREA)
Food Science & Technology (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
General Physics & Mathematics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Investigating Or Analysing Biological Materials (AREA)
Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)

CA000556618A 1987-01-15 1988-01-15 Methode pour la detection et la quantification des ligands dans des liquides Expired - Lifetime CA1297406C (fr)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US360487A	1987-01-15	1987-01-15
US356687A	1987-01-15	1987-01-15
US003,604		1987-01-15
US003,566		1987-01-15
US07/013,581 US4863876A (en)	1987-01-15	1987-02-11	Method of detecting and quantifying ligands in liquids via biotin-avidin-medicated fluorescence polarization
US013,581		1987-02-11

Publications (1)

Publication Number	Publication Date
CA1297406C true CA1297406C (fr)	1992-03-17

Family

ID=27357435

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000556618A Expired - Lifetime CA1297406C (fr)	1987-01-15	1988-01-15	Methode pour la detection et la quantification des ligands dans des liquides

Country Status (4)

Country	Link
JP (1)	JPH02502122A (fr)
AU (1)	AU1342488A (fr)
CA (1)	CA1297406C (fr)
WO (1)	WO1988005538A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IE64286B1 (en) *	1988-05-25	1995-07-26	Boehringer Mannheim Gmbh	Process for the determination of an immunologically detectable substance and a suitable vessel therefor
DE3834766A1 (de) *	1988-10-12	1990-04-26	Boehringer Mannheim Gmbh	Verfahren zur bestimmung einer spezifisch bindefaehigen substanz
GB8902689D0 (en) *	1989-02-07	1989-03-30	Ici Plc	Assay method
US6087188A (en) *	1992-11-13	2000-07-11	Alk A/S	Two-site immunoassay for an antibody with chemiluminescent label and biotin bound ligand
US6503709B1 (en)	1997-07-03	2003-01-07	Id Biomedical Corporation	Methods for rapidly detecting methicillin resistant staphylococci
DE60238928D1 (de) *	2001-09-19	2011-02-24	Masaaki Kai	Lumineszierendes polymer und seine verwendung im bioassay
CN107533052B (zh) *	2015-05-11	2023-04-28	万迈医疗仪器有限公司	在免疫测定中重复使用测试探针和试剂的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0201211A1 (fr) *	1985-04-10	1986-11-12	Whittaker Corporation	Méthode et compositions pour immuno-essais visuels à phase solide basés sur des particules microsphériques et luminescente

1988
- 1988-01-14 JP JP63501878A patent/JPH02502122A/ja active Pending
- 1988-01-14 AU AU13424/88A patent/AU1342488A/en not_active Abandoned
- 1988-01-14 WO PCT/US1988/000067 patent/WO1988005538A1/fr not_active Ceased
- 1988-01-15 CA CA000556618A patent/CA1297406C/fr not_active Expired - Lifetime

Also Published As

Publication number	Publication date
JPH02502122A (ja)	1990-07-12
WO1988005538A1 (fr)	1988-07-28
AU1342488A (en)	1988-08-10

Legal Events

Date	Code	Title	Description
1995-09-18	MKLA	Lapsed

Publication	Publication Date	Title
US4863876A (en)	1989-09-05	Method of detecting and quantifying ligands in liquids via biotin-avidin-medicated fluorescence polarization
US4923819A (en)	1990-05-08	Time-resolved fluorescence immunoassay
US5464741A (en)	1995-11-07	Palladium (II) octaethylporphine alpha-isothiocyanate as a phosphorescent label for immunoassays
US6743640B2 (en)	2004-06-01	Fluorescent polymer-QTL approach to biosensing
US20090263914A1 (en)	2009-10-22	Bioanalytical assay
Gribnau et al.	1986	Particle-labelled immunoassays: a review
US4231750A (en)	1980-11-04	Methods for performing chemical assays using fluorescence and photon counting
AU2016246603B2 (en)	2019-08-15	Bioconjugates of heterocyclic compounds
AU682478B2 (en)	1997-10-09	Two-site immunoassay for an antibody with chemiluminescent label and biotin bound ligand
CA1297406C (fr)	1992-03-17	Methode pour la detection et la quantification des ligands dans des liquides
Patel et al.	1983	Chemiluminescence energy transfer: a new technique applicable to the study of ligand-ligand interactions in living systems
CN114324862A (zh)	2022-04-12	一种非洲猪瘟病毒均相检测反应试剂及检测方法
Bertoft et al.	1984	Competitive solid-phase immunoassay of testosterone using time-resolved fluorescence
US5202269A (en)	1993-04-13	Method for immunochemical determination of hapten
Diamandis et al.	1988	Time-resolved fluoroimmunoassay of cortisol in serum with a europium chelate as label
CA1284620C (fr)	1991-06-04	Mesure de la concentration d'un analyte en utilisant deux marqueurs
Chan	1987	General principle of immunoassay
EP0886754A1 (fr)	1998-12-30	Dosage immunologique non competitif a blocage de sites de liaison specifiques non occupes en phase solide
CA1300808C (fr)	1992-05-12	Dosage immunologique a polarisation de fluorescence et reactifs de mesure de la proteine c-reactive
Khosravi et al.	1991	Novel application of streptavidin-hapten derivatives as protein-tracer conjugate in competitive-type immunoassays involving biotinylated detection probes
JPH0758291B2 (ja)	1995-06-21	アナライトが存在可能な媒体中のアナライトをルミネセンスによって検出および／または測定するための均質方法およびその方法に使用するキット
CA2246894C (fr)	2007-08-07	Surfaces de liaison pour ligands
Barnard	1999	Time-resolved fluorescence immunoassay
Shankaran	1988	IMMUNOFLUOROMETRY TO THE ATTOMOLAR RANGE AFTER NOVEL MULTIPLE LABELLING OF STREPTAVIDIN. RC Morton. E. Reichstein, M.. L Khosravi and EP Diamandis (CyberFluor Inc., 179 John Street, Toronto, Ontario, Canada M5T 1X4) Multiple fluorescence labelling with conventional probes like fluorescein, to
Diamandis et al.	1988	MC-1 A new generation of time-resolved fluoroimmunoassays with europium chelates as labels